Skip navigation
  •  Home
  • UDC 
    • Getting started
    • RUC Policies
    • FAQ
    • FAQ on Copyright
    • More information at INFOguias UDC
  • Browse 
    • Communities
    • Browse by:
    • Issue Date
    • Author
    • Title
    • Subject
  • Help
    • español
    • Gallegan
    • English
  • Login
  •  English 
    • Español
    • Galego
    • English
  
View Item 
  •   DSpace Home
  • 1. Investigación
  • Instituto de Investigación Biomédica da Coruña (INIBIC)
  • Viroloxía clínica
  • INIBIC-VC - Artigos
  • View Item
  •   DSpace Home
  • 1. Investigación
  • Instituto de Investigación Biomédica da Coruña (INIBIC)
  • Viroloxía clínica
  • INIBIC-VC - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients

Thumbnail
View/Open
Rodriguez_Real.pdf (153.7Kb)
Use this link to cite
http://hdl.handle.net/2183/18395
Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España
Collections
  • INIBIC-VC - Artigos [37]
Metadata
Show full item record
Title
Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients
Author(s)
Rodríguez-Osorio, Iria
Cid-Silva, Purificación
Morano, Luis
Castro-Iglesias, Ángeles
Suárez, Marta
Delgado, Manuel
Margusino-Framiñán, Luis
Meijide, Héctor
Pernas, Berta
Tabernilla, Andrés
Pedreira, José D.
Mena, Álvaro
Poveda, Eva
Date
2017-01-18
Citation
61
Abstract
[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and are on chronic medications. Study design. All HCV-infected patients over 65 years old in clinical follow-up at two Hospitals in Spain who initiated anti-HCV therapy were included (August 2012–October 2015). Results. A total of 120 HCV mono-infected patients were recorded. Mean age of patients was 72.6 ± 7.4 years. There were 53.3% women and GT1b was the most frequent (83.3%); 64.2% had cirrhosis and 42.5% were treatment experienced. Ombitasvir + Paritaprevir/r ± Dasabuvir ± Ribavirin (RBV) and sofosbuvir/ledipasvir ± RBV were the most frequently used regimens. Weight-adjusted dosing of RBV was included in 61.7% and 43.6% of them required a dose reduction. Most of the patients (86.7%) had concomitant chronic medication and in 35.8% adjustment was necessary. Adverse events (AE) were seen in 65% of the patients; more frequent when a protease inhibitor (PI) was being used. The sustained virological response (SVR12) per ITT was 88.3%. Only 3 patients discontinued treatment and 2 patients died. Conclusions. High rates of SVR12 (88.3%) were observed among elderly patients with DAAs-based regimens. The presence of AE was frequent (65%). The majority of these patients (86.7%) had concomitant medication that required adjustment in 1/3 of them. These findings highlight the high rates of response to DAAs in the elderly HCV-population. However, special caution must be taken when using RBV and a PI.
Description
Short communication
Editor version
http://doi.org/10.1016/j.jcv.2017.01.003
Rights
Atribución-NoComercial-SinDerivadas 3.0 España
ISSN
1386-6532
1873-5967
 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

View Usage Statistics
Sherpa
OpenArchives
OAIster
Scholar Google
UNIVERSIDADE DA CORUÑA. Servizo de Biblioteca.    DSpace Software Copyright © 2002-2013 Duraspace - Send Feedback